Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 25-30

  Hsieh, Li En ^a   Lin, Chao Nan ^a   Su, Bi Ling ^a   Jan, Tong Rong ^a   Chen, Chi Min ^b   Wang, Ching Ho ^a   Lin, Dah Sheng ^a   Lin, Chung Tien ^a   Chueh, Ling Ling ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

Author keywords

Antiviral agent; Feline coronavirus; Galanthus nivalis agglutinin; Nelfinavir; Synergistic effect

Indexed keywords

ACICLOVIR; AGGLUTININ; ATAZANAVIR; EFAVIRENZ; EMODIN; IDOXURIDINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROMAZINE; RIBAVIRIN; SAQUINAVIR; STAVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CELL STRAIN FCWF 4; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS; DRUG POTENTIATION; DRUG SCREENING; FELINE INFECTIOUS PERITONITIS; FETUS; GALANTHUS; GALANTHUS NIVALIS; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CATS; CELLS, CULTURED; CORONAVIRUS, FELINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FELINE INFECTIOUS PERITONITIS; FETUS; GALANTHUS; MANNOSE-BINDING LECTINS; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; PLANT LECTINS; VIRUS REPLICATION;

FELIDAE; FELINE CORONAVIRUS; FELIS CATUS; GALANTHUS NIVALIS;

EID: 77956893950     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.06.010     Document Type: Article

References (32)

1. Addie D.D., Paltrinieri S., Pedersen N.C. Recommendations from workshops of the second international feline coronavirus/feline infectious peritonitis symposium. J. Feline Med. Surg. 2004, 6:125-130.
2. Atrasheuskaya A., Petzelbauer P., Fredeking T.M., Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 2003, 35:33-42.
3. Barlough J.E., Scott F.W. Effectiveness of three antiviral agents against FIP virus in vitro. Vet. Rec. 1990, 126:556-558.
4. Christianson K.K., Ingersoll J.D., Landon R.M., Pfeiffer N.E., Gerber J.D. Characterization of a temperature sensitive feline infectious peritonitis coronavirus. Arch. Virol. 1989, 109:185-196.
5. de Groot-Mijnes J.D., van Dun J.M., van der Most R.G., de Groot R.J. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J. Virol. 2005, 79:1036-1044.
6. Hartmann K. Feline infectious peritonitis. Vet. Clin. North. Am. Small Anim. Pract. 2005, 35:39-79. vi.
7. Hartmann K., Ritz S. Treatment of cats with feline infectious peritonitis. Vet. Immunol. Immunopathol. 2008, 123:172-175.
8. Ho T.Y., Wu S.L., Chen J.C., Li C.C., Hsiang C.Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007, 74:92-101.
9. Kaldor S.W., Kalish V.J., Davies J.F., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., Dressman B.A., Hatch S.D., Khalil D.A., Kosa M.B., Lubbehusen P.P., Muesing M.A., Patick A.K., Reich S.H., Su K.S., Tatlock J.H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40:3979-3985.
10. Keyaerts E., Vijgen L., Pannecouque C., Van Damme E., Peumans W., Egberink H., Balzarini J., Van Ranst M. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 2007, 75:179-187.
11. Kipar A., Baptiste K., Barth A., Reinacher M. Natural FCoV infection: cats with FIP exhibit significantly higher viral loads than healthy infected cats. J. Feline Med. Surg. 2006, 8:69-72.
12. Lewis J.S., Terriff C.M., Coulston D.R., Garrison M.W. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin. Ther. 1997, 19:187-214.
13. Lin C.N., Su B.L., Wang C.H., Hsieh M.W., Chueh T.J., Chueh L.L. Genetic diversity and correlation with feline infectious peritonitis of feline coronavirus type I and II: a 5-year study in Taiwan. Vet. Microbiol. 2009, 136:233-239.
14. Lin C.N., Su B.L., Wu C.W., Hsieh L.E., Chueh L.L. Isolation and identification of a novel feline coronavirus from a kitten with naturally occurring feline infectious peritonitis in Taiwan. Taiwan Vet. J. 2009, 35:145-152.
15. Murphy K., Travers P., Walport M. Basic concepts in immunology. Janeway's Immunobiology 2008, Garland Science, New York. 7th ed. K. Murphy, P. Travers, M. Walport (Eds.).
16. Paltrinieri S. Human severe acute respiratory syndrome (SARS) and feline coronaviroses. J. Feline Med. Surg. 2004, 6:131-132.
17. Perlman S., Dandekar A.A. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 2005, 5:917-927.
18. Rajnarayanan R.V., Dakshanamurthy S., Pattabiraman N. " Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs. Biochem. Biophys. Res. Commun. 2004, 321:370-378.
19. Reed L.J., Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
20. Scott F.W. Immunization against feline coronaviruses. Adv. Exp. Med. Biol. 1987, 218:569-576.
21. Stoddart C.A., Barlough J.E., Baldwin C.A., Scott F.W. Attempted immunisation of cats against feline infectious peritonitis using canine coronavirus. Res. Vet. Sci. 1988, 45:383-388.
22. Takano T., Hohdatsu T., Hashida Y., Kaneko Y., Tanabe M., Koyama H. A " possible" involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet. Microbiol. 2007, 119:121-131.
23. Takano T., Hohdatsu T., Toda A., Tanabe M., Koyama H. TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 2007, 364:64-72.
24. Tan E.L., Ooi E.E., Lin C.Y., Tan H.C., Ling A.E., Lim B., Stanton L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 2004, 10:581-586.
25. van der Meer F.J., de Haan C.A., Schuurman N.M., Haijema B.J., Peumans W.J., Van Damme E.J., Delputte P.L., Balzarini J., Egberink H.F. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res. 2007, 76:21-29.
26. van der Meer F.J., de Haan C.A., Schuurman N.M., Haijema B.J., Verheije M.H., Bosch B.J., Balzarini J., Egberink H.F. The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J. Antimicrob. Chemother. 2007, 60:741-749.
27. Vennema H., de Groot R.J., Harbour D.A., Dalderup M., Gruffydd-Jones T., Horzinek M.C., Spaan W.J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 1990, 64:1407-1409.
28. Vennema H., de Groot R.J., Harbour D.A., Dalderup M., Gruffydd-Jones T., Horzinek M.C., Spaan W.J. Immunogenicity of recombinant feline infectious peritonitis virus spike protein in mice and kittens. Adv. Exp. Med. Biol. 1990, 276:217-222.
29. Weiss R.C., Cox N.R., Martinez M.L. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res. Vet. Sci. 1993, 55:162-172.
30. Weiss R.C., Oostrom-Ram T. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet. Microbiol. 1989, 20:255-265.
31. Yamamoto N., Yang R., Yoshinaka Y., Amari S., Nakano T., Cinatl J., Rabenau H., Doerr H.W., Hunsmann G., Otaka A., Tamamura H., Fujii N. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 2004, 318:719-725.
32. Zhang X.W., Yap Y.L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg. Med. Chem. 2004, 12:2517-2521.